First Clinical Trial Patient in the World Enrolled in New Trial
The ECHO Research Department recently hosted Valerie Gabarre, MD (Medical Director) and Berangere Vasseu, MD (Chief Medical Officer) from the French company OSE Immunotherapeutics. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation.
The OSE medical team recently flew from France to congratulate the ECHO research team for enrolling the first patient in the world in a recent trial and identifying other potential patients for the study.
Drs. Gabarre and Vasseu met with Dr. Slater, (Principal Investigator), Dr. Johnson (Director of Research), Nancy Wilcox, BS,RN (Nurse Study Coordinator), James Champlin (Study Coordinator), Stephanie Pacheco (Regulatory Assistant) and Spiro Curis, MD (Inventory Specialist) to review the clinical trial.
About the Clinical Trial
ECHO is participating in the ARTEMIA clinical study, A Trial of Therapeutic Cancer Vaccine OSE2101 in Patients with Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor.
Patients who have progressed after first line treatment of chemotherapy and immunotherapy for non-small cell lung cancer are treated with additional chemotherapy or invited to participate in a clinical trial.
This clinical trial is designed to compare OSE2101 vaccine to the standard of care chemotherapy docetaxel. OSE2101 is a therapeutic cancer vaccine composed of multiple peptides designed to stimulate the immune system to induce cytotoxic T lymphocytes against five tumor-associated antigens frequently overexpressed in NSCLC.
Who Can Participate in this Trial
We are actively prescreening patients for this trial. Patients must be HLA-2 positive to participate in the clinical trial. HLA-2 is type of human leukocyte antigen (HLA) that plays a crucial role in the immune system by presenting antigens to CD4+ T cells. HLA-2 molecules present processed antigens, which are derived from the vaccine to CD4+ T cells. This presentation is essential for initiating antigen-specific immune responses. If patients are HLA-2 positive, they will be invited to participate in the ARTEMIA trial.
Participating in this Trial
All details of the study will be discussed with the patient and if the patient agrees to participate, they will be consented into the trial. Consented HLA-2 positive participants will undergo screening to assess inclusion/exclusion criteria for the clinical trial. The next step is randomization to the trial. The randomization is 2:1 (OSE2101 vaccine vs. docetaxel chemotherapy). The study coordinator will work closely with the patient throughout the study.
Click here to learn about other clinical trials currently being offered at ECHO. Check back regularly since our Research team continues to offer the latest clinical trials to meet the needs of our patient population.